Lupin announced positive topline result from Phase 3 study for trichomoniasis treatment

Based on the data, Lupin plans to submit a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (USFDA) for Solosec for the treatment of trichomoniasis in the second half of 2020.

from India Infoline News Service https://ift.tt/2YzT5U0